Chicago—Results from a Phase III trial in China support gemcitabine plus cisplatin as standard first-line therapy for patients with recurrent or metastatic nasopharyngeal cancer. Compared with the commonly used therapy of 5-fluorouracil (5-FU) plus cisplatin, gemcitabine plus cisplatin increased median progression-free survival (PFS) by 1.5 months and median overall survival (OS) by nine months.
“Our study is the first head-to-head, randomized, Phase III study in first-line